• 1
    DiBartola SP, Rutgers HC, Zack PM, et al. Clinicopathologic findings associated with chronic renal disease in cats: 74 cases (1973–1984). J Am Vet Med Assoc 1987;190:11961202.
  • 2
    Elliott J., Barber PJ. Feline chronic renal failure: Clinical findings in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract 1998;39: 7885.
  • 3
    Barber PJ, Elliott J. Feline chronic renal failure: Calcium homeostasis in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract 1998;39: 108116.
  • 4
    Slatopolsky E., Caglar S., Pennell JP, et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 1971;50:492499.
  • 5
    Tanaka Y., Deluca HF. The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys 1973;154:566574.
  • 6
    Portale AA, Booth BE, Halloran BP, et al. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984;73:15801589.
  • 7
    Brown AJ, Dusso A., Lopez-Hilker S., et al. 1,25-(OH)2D receptors are decreased in parathyroid glands from chronically uremic dogs. Kidney Int 1989;35:1923.
  • 8
    Korkor AB. Reduced binding of [3H] 1, 25-dihydroxy vitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 1987;316:15731577.
  • 9
    Merke J., Hugel U., Zlotkowski A., et al. Diminished parathyroid 1,25 (OH)2D3 receptors in experimental uremia. Kidney Int 1987;32: 350353.
  • 10
    Patel SR, Ke HQ, Vanholder R., et al. Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest 1995;96:5059.
  • 11
    Yalcindag C., Silver J., Naveh-Many T. Mechanism of increased parathyroid hormone mRNA in experimental uremia: Roles of protein RNA binding and RNA degradation. J Am Soc Nephrol 1999;10:25622568.
  • 12
    Martin KJ, Gonzalez EA, Slatopolsky E. Renal osteodystrophy. In: BrennerBM, RectorFC, eds. Brenner and Rector's The Kidney, 7th ed. St Louis , MO : Elsevier; 2004: 22552293.
  • 13
    Massry SG. Pathogenesis of the anemia of uremia: Role of secondary hyperparathyroidism. Kidney Int Suppl 1983: 16: S204207.
  • 14
    Brown SA, Crowell WA, Barsanti JA, et al. Beneficial effects of dietary mineral restriction in dogs with marked reduction of functional renal mass. J Am Soc Nephrol 1991;1:11691179.
  • 15
    Kaplan MA, Canterbury JM, Bourgoignie JJ, et al. Reversal of hyperparathyroidism in response to dietary phosphorus restriction in the uremic dog. Kidney Int 1979;15:4348.
  • 16
    Barber PJ, Rawlings JM, Mark Well PJ, et al. Effect of dietary phosphate restriction on renal secondary hyperparathyroidism in the cat. J Small Anim Pract 1999;40:6270.
  • 17
    Elliott J., Rawlings JM, Mark Well PJ, et al. Survival of cats with naturally occurring chronic renal failure: Effect of dietary management. J Small Anim Pract 2000;41:235242.
  • 18
    Ross LA, Finco DR, Crowell WA. Effect of dietary phosphorus restriction on the kidneys of cats with reduced renal mass. Am J Vet Res 1982;43:10231026.
  • 19
    Slatopolsky E., Weerts C., Thielan J., et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984;74:21362143.
  • 20
    Martin KJ, Ballal HS, Domoto DT, et al. Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: Preliminary observations. Am J Kidney Dis 1992;19:540545.
  • 21
    Naveh-Many T., Rahamimov R., Livni N., et al. Parathyroid cell proliferation in normal and chronic renal failure rats: The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995;96:17861793.
  • 22
    Wang Q., Palnitkar S., Parfitt AM. Parathyroid cell proliferation in the rat: Effect of age and of phosphate administration and recovery. Endocrinology 1996;137:45584562.
  • 23
    Szotkiewicz M., Zdrojewski Z., Swima-Gillow A., et al. Can hypercalcaemia be avoided during oral calcitriol pulse therapy of secondary hyperparathyroidism in haemodialysis patients Nephrol Dial Transplant 1995;10:17811782.
  • 24
    Chew DJ, Nagode LA. Calcitriol in the treatment of chronic renal failure. In: KirkRW, BonaguraJD, eds. Current Veterinary Therapy XI. Philadelphia , PA : WB Saunders; 1992: 857860.
  • 25
    Nagode LA, Chew DJ, Podell M. Benefits of calcitriol therapy and serum phosphorus control in dogs and cats with chronic renal failure: Both are essential to prevent of suppress toxic hyperparathyroidism. Vet Clin North Am Small Anim Pract 1996;26:12931330.
  • 26
    Torrance AG, Nachreiner R. Human-parathormone assay for use in dogs: Validation, sample handling studies, and parathyroid function testing. Am J Vet Res 1989;50:11231127.
  • 27
    DeLuca HF. The metabolism, physiology, and function of vitamin D. In: KumarR., ed. Vitamin D: Basic and Clinical Aspects. Boston , MA : Martinus Nijhoff; 1984: 168.
  • 28
    Dusso AS, Negrea L., Gunawardhana S., et al. On the mechanisms for the selective action of vitamin D analogs. Endocrinology 1991;128:16871692.
  • 29
    Gerber B., Hassig M., Reusch CE. Serum concentrations of 1,25-dihydroxycholecalciferol and 25-hydroxycholecalciferol in clinically normal dogs and dogs with acute and chronic renal failure. Am J Vet Res 2003;64:11611166.
  • 30
    Brown SA, Finco DR. Reassessment of the use of calcitriol in chronic renal failure. In: BonaguraJD, ed. Kirk's Current Veterinary Therapy XII. Philadelphia : WB Saunders; 1995: 963966.